Financials in USD. Standardized financial statements.
A compact view of how Cannara Biotech Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $107.32M | $81.75M | $57.26M | $35.84M | $17.02M | $2.55M | $2.10M | $432,637 |
| Revenue Growth? | +31.3% | +42.8% | +59.8% | +110.6% | +567.2% | +21.6% | +384.7% | 0.0% |
| Cost of Revenue? | $60.10M | $51.96M | $30.03M | $18.51M | $6.72M | $1.33M | $403,895 | $273,580 |
| Gross Profit? | $47.22M | $29.79M | $27.23M | $17.33M | $10.30M | $1.22M | $1.69M | $159,057 |
| Gross Margin? | +44.0% | +36.4% | +47.6% | +48.4% | +60.5% | +48.0% | +80.7% | +36.8% |
| Operating Expenses? | $25.02M | $19.71M | $15.34M | $12.36M | $10.00M | $13.15M | $11.92M | $1.98M |
| Operating Income? | $22.20M | $10.08M | $11.89M | $4.94M | $257,283 | -$11.95M | -$10.22M | -$1.82M |
| EBITDA? | $28.18M | $15.16M | $15.77M | $8.40M | $3.06M | -$9.19M | -$10.89M | -$1.68M |
| Income Before Tax | $18.10M | $4.48M | $6.95M | $2.31M | -$1.53M | -$13.09M | -$12.97M | -$2.11M |
| Income Tax Expense | $5.02M | -$1.95M | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | $13.08M | $6.44M | $6.95M | $2.31M | -$1.53M | -$12.48M | -$12.32M | -$2.11M |
| EPS? | $0.14 | $0.06 | $0.08 | $0.03 | $-0.02 | $-0.17 | $-0.17 | $-0.03 |
| Diluted EPS? | $0.14 | $0.07 | $0.08 | $0.03 | $-0.02 | $-0.17 | $-0.17 | $-0.03 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality